^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anti-EphA2 CAR-T therapy

    i
    Other names: Anti-EphA2 CAR-T therapy
    Associations

    News

    Trials
    Company:
    SenlangBio
    Drug class:
    EphA2-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    over4years
    Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas (clinicaltrials.gov)
    P1, N=100, Recruiting, Xuanwu Hospital, Beijing | Trial completion date: Jan 2021 --> Jan 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    Anti-EphA2 CAR-T therapy
    6years
    Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas (clinicaltrials.gov)
    P1, N=100, Recruiting, Xuanwu Hospital, Beijing | N=50 --> 100 | Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    Anti-EphA2 CAR-T therapy